Chemical Structure For Cilostazol (Image 1)
Cilostazol Tablet
Product Images NDC 0093-2064
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cilostazol (NDC 0093-2064). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Image 2)
This is a chart showing the plasma concentration (in ng/mL) of cilostazol and its metabolites over time (in hours). There are three substances being measured: cilostazol, 3,4-dehydrocilostazol, and 4'-trans-hydroxycilostazol. The chart displays values at 12, 16, 20, and 24 hours.*
Figure 2 (Image 3)
Percent Mean Improvement in Maximal Walking Distance for patients treated with Cilostazol 50 mg and Cilostazol 100 mg b.i.d. The data is presented in a graph with 3 different durations of treatment: 24 weeks, 16 weeks, and 12 weeks.*
Image (Image 4)
This is a medication information leaflet for Cilostazol Tablets USP containing 50mg cilostazol. It indicates that the usual dosage is 1 tablet and advises keeping the medication out of reach of children. The leaflet provides the drug code, recommends dispensing with the attached patient information leaflet, and mentions a resistant closure on the packaging. All the other text is either identification numbers and dates or illegible.*
Image (Image 5)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
